It’s certainly not Breaking News that M&A deals are an important source of liquidity in biotech VC today. But last year did mark an important milestone for biotech over the past few years: in 2011, the capital returned to investors from private M&A alone likely exceeded the total capital invested into private biotech companies.
2011 was a banner year for private company M&A. Based on the data compiled by BioCentury, and Walter Yang in particular, deal values were up over 3x since the nadir of 2008. Here’s the snapshot:
- 64 private M&A deals closed in 2011, representing $23B in proceeds (upfronts and milestones). This includes great deals like Plexxikon/Daiichi, Calistoga/Gilead, Amira/BMS, BioVex/Amgen and Advanced BioHealing/Shire, among others.
- Only 45 of these 64 deals disclosed financial information
To read the full, original article click on this link: Venture-Backed Biotech's 2011 M&A Exits Outpaced Both Investments and Fundraising - Forbes
